Abstract
The generation of a strong antibody response to target antigens is a major goal for vaccine development. Here we describe the display of the human immunodeficiency virus (HIV) envelope spike protein (Env) on a virus-like scaffold provided by the lambda phage capsid. Phage vectors, in general, have advantages over mammalian virus vectors due to their genetic tractability, inexpensive production, suitability for scale-up, as well as their physical stability, making them an attractive vaccine platform.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Burton DR (2006) Structural biology: images from the surface of HIV. Nature 441(7095):817–818
Pantophlet R, Burton DR (2006) GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 24:739–769
Zolla-Pazner S (2004) Identifying epitopes of HIV-1 that induce protective antibodies. Nat Rev Immunol 4(3):199–210
McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman MR (1984) Human hepatitis B vaccine from recombinant yeast. Nature 307(5947):178–180
Evans TG, Bonnez W, Rose RC, Koenig S, Demeter L, Suzich JA et al (2001) A Phase 1 study of a recombinant virus like particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis 183(10):1485–1493
Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A et al (2004) Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364(9447):1757–1765
Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR et al (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6(5):271–278
Lee DH, Lee SH, Kim AR, Quan FS (2016) Virus-like nanparticle vaccine confers protection against Toxoplasma gondii. PLoS One. 11(8). doi:10.1371/journal.pone.0161231
Merril CR, Scholl D, Adhya SL (2003) The prospect for bacteriophage therapy in Western medicine. Nat Rev Drug Discov 2(6):489–497
Fogelman I, Davey V, Ochs HD, Elashoff M, Feinberg MB, Mican J et al (2000) Evaluation of CD4+ T cell function In vivo in HIV-infected patients as measured by bacteriophage phiX174 immunization. J Infect Dis 182(2):435–441
Piersanti S, Cherubini G, Martina Y, Salone B, Avitabile D, Grosso F et al (2004) Mammalian cell transduction and internalization properties of lambda phages displaying the full-length adenoviral penton base or its central domain. J Mol Med 82(7):467–476
Yang F, Forrer P, Dauter Z, Conway JF, Cheng N, Cerritelli ME et al (2000) Novel fold and capsid- binding properties of the lambda-phage display platform protein gpD. Nat Struct Biol 7(3):230–237
Sternberg N, Hoess RH (1995) Display of peptides and proteins on the surface of bacteriophage lambda. Proc Natl Acad Sci 92(5):1609–1613
Domm W, Brewer M, Baker SF, Feng C, Martinez-Sobrido L, Treanor J, Dewhurst S (2014) Use of bacteriophage particles displaying influenza virus hemagglutnin for the detection of hemagglutination-inhibition antibodies. J Virol Methods 197:47–50 Vaccine 29(14):2637–2647
Mattiacio J, Walter S, Brewer M, Domm W, Friedman AE, Dewhurst S (2011) Dense display of HIV-1 envelope spikes on the lambda phage scaffold does not result in the generation of improved antibody respones to HIV-1 Env. Vaccine 29(14):2637–2647
Eguchi A, Akuta T, Okuyama H, Senda T, Yokoi H, Inokuchi H et al (2001) Protein transduction domain of HIV-1 Tat protein promotes efficient delivery of DNA into mammalian cells. J Biol Chem 276(28):26204–26210
Zanghi CN, Lankes HA, Bradel-Tretheway B, Wegman J, Dewhurst S (2005) A simple method for displaying recalcitrant proteins on the surface of bacteriophage lambda. Nucleic Acids Res 33(18):e160. doi:10.1093/nar/gni 158
Zanghi CN, Sapinoro R, Bradel-Tretheway B, Dewhurst S (2007) A tractable method for simultaneous modifications to the head and tail of bacteriophage lambda and its application to enhancing phage-mediated gene delivery. Nucleic Acids Res 35(8):e59. doi:10.1093/nar/gkm146
Sambrook J, Russell DW (2006) Purification of bacteriophage λ particles by isopycnic centrifucation through CsCl gradients. Cold Spring Harb Protoc. doi:10.1101/pdb.prot3968
Acknowledgment
This work was supported by NIH grant R21A1074351 (S.D.), T32DE007202 (J.M.) and T32AI049815 (M.B.).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this protocol
Cite this protocol
Mattiacio, J.L., Brewer, M., Dewhurst, S. (2017). Display of HIV-1 Envelope Protein on Lambda Phage Scaffold as a Vaccine Platform. In: Ferran, M., Skuse, G. (eds) Recombinant Virus Vaccines. Methods in Molecular Biology, vol 1581. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6869-5_14
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6869-5_14
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-6867-1
Online ISBN: 978-1-4939-6869-5
eBook Packages: Springer Protocols